On Tuesday, TG Therapeutics hit an important technical milestone, with its Relative Strength (RS) Rating jumping into the 90-plus percentile with an upgrade to 91, a rise from 87 the day before.
This exclusive rating from Investor's Business Daily measures share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks typically have an 80 or better RS Rating at the beginning of a new run.
How To Use Stock Charts To Stay Profitable And Protected
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to form a base and break out.
TG Therapeutics posted 0% EPS growth in its most recent report, while sales growth came in at 714%.
TG Therapeutics earns the No. 22 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
